CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, announced today that its proprietary gamma sensory stimulation at 40Hz over a 6-month period reduced white matter atrophy in the brain for ...

Iowa State University researchers have identified a protein essential for building memories that appears to predict the progression of memory loss and brain atrophy in Alzheimer's patients. Auriel ...

A recent study by the Laboratory for Neuro-Analysis and Imaging (LANAI) at UMass Chan Medical School highlights how ...

New research reveals that air pollution, especially PM2.5, may contribute to cerebral atrophy but does not seem to impair cognitive function. Urbanization affects the strength of this link. Study: ...

In Europe, Science has applied for regulatory approval and hopes to have PRIMA available to patients later this year. In the United States, a Food and Drug Administration approval process is underway.

Brain volume loss is a key marker of degeneration in multiple sclerosis, correlated with future disability progression. Ponesimod, alemtuzumab, teriflunomide, ozanimod, and fingolimod significantly ...

MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...